ALLO News and Press, Allogene Therapeutics Inc. From 05/19/21

ALLO-501 ALPHA Trial Produced Durable Complete Responses (CR) with Longest Ongoing CR at 15 Months in Both Large B Cell Lymphoma (LBCL) and Follicular Lymphoma (FL) Overall Response Rate (ORR) of 75% and CR Rate of 50% Across Histologies in CAR T Naïve Patients, on Par with Dat...

Fate's early stage data look promising: JefferiesFate Therapeutics (FATE) shares shed ~1.4% after the company announced data from an early stage leukemia trial for its natural killer ((NK)) cell programs.Fate has lost ~21.3% in the year so far and noting that data looked promising and have de...

Webinar Scheduled for 2:30 PM PT/5:30 PM ET SOUTH SAN FRANCISCO, Calif., May 12, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer will...

Allogene Therapeutics, Inc. (ALLO) Q1 2021 Earnings Conference Call May 05, 2021, 05:00 PM ET Company Participants Christine Cassiano - CCO David Chang - President and CEO Rafael Amado - EVP-Research and Development and CMO Eric Schmidt - CFO Conference Call Participants Salveen Richter - Gol...

Allogene Therapeutics (ALLO): Q1 GAAP EPS of -$0.25 beats by $0.21.Revenue of $38.35M beats by $26.42M.Press Release For further details see: Allogene Therapeutics EPS beats by $0.21, beats on revenue

CD19 Program Highlights Data from the ALLO-501 ALPHA Study and ALLO-501A ALPHA2 Study to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting Longer Term Follow-Up from the ALPHA Study and Consolidation Dosing in Both ALPHA and ALPHA2 Study to be I...

Longer Term Data from the ALLO-501 Phase 1 ALPHA Study to be Presented Alongside Initial Data from the Phase 1 ALLO-501A ALPHA2 Study Separate Presentation to Include Safety and PK/PD Data on ALLO-647 Used in, Allogene’s Proprietary Lymphodepletion Regimen ALLO-501A, Intend...

SOUTH SAN FRANCISCO, Calif., April 27, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that it will report first quarter 2021 ...

The FDA has granted Regenerative Medicine Advanced Therapy ((RMAT)) designation to Allogene Therapeutics' (ALLO) ALLO-715 in relapsed/refractory multiple myeloma.RMAT is akin to Breakthrough Therapy status for drugs/biologics. It provides for the accelerated review of the marketing applicatio...

RMAT Designation Follows Proof-of-Concept Data from ALLO-715 UNIVERSAL Trial in Heavily Pretreated, Refractory Multiple Myeloma Patients UNIVERSAL Trial Demonstrated for the First Time that an Allogeneic CAR T Therapy Directed at BCMA Can Achieve Clinical Responses While Eliminating...